|
Mink Therapeutics, Inc. (INKT) Évaluation DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
MiNK Therapeutics, Inc. (INKT) Bundle
Prenez en charge votre analyse d'évaluation de Kink Therapeutics, Inc. (INKT) avec notre calculatrice DCF de pointe! Ce modèle Excel est préchargé avec des données réelles (INKT), vous permettant d'ajuster les prévisions et les hypothèses pour un calcul précis de la valeur intrinsèque de Mink Therapeutics, Inc.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .7 | .0 | .0 | 2,704.7 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | -100 | 0 | 0 | -100 | -50 | -50 | -50 | -50 | -50 |
| EBITDA | -22.2 | -13.7 | -27.7 | -30.8 | -22.3 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | -3219.79 | 100 | 100 | -1.14 | 100 | 39.77 | 39.77 | 39.77 | 39.77 | 39.77 |
| Depreciation | .0 | .1 | .1 | .1 | .2 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 5.34 | 100 | 100 | 0.00450131 | 100 | 61.07 | 61.07 | 61.07 | 61.07 | 61.07 |
| EBIT | -22.2 | -13.8 | -27.8 | -30.9 | -22.5 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | -3225.13 | 100 | 100 | -1.14 | 100 | 39.77 | 39.77 | 39.77 | 39.77 | 39.77 |
| Total Cash | .3 | 2.7 | 38.9 | 19.6 | 3.4 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 0 | 100 | 100 | 0 | 100 | 60 | 60 | 60 | 60 | 60 |
| Inventories | .1 | 1.0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 12.72 | 100 | 100 | 0 | 100 | 62.54 | 62.54 | 62.54 | 62.54 | 62.54 |
| Accounts Payable | 2.5 | 3.1 | 3.0 | 5.8 | 3.9 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 356.16 | 100 | 100 | 0.21529 | 100 | 80.04 | 80.04 | 80.04 | 80.04 | 80.04 |
| Capital Expenditure | -.4 | -.1 | -.2 | -.3 | -.1 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | -61.84 | 100 | 100 | -0.00924472 | 100 | -12.37 | -12.37 | -12.37 | -12.37 | -12.37 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -24.2 | -13.3 | -21.3 | -27.4 | -22.5 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -22.2 | -13.6 | -20.6 | -24.7 | -24.2 | -3.9 | .0 | .0 | .0 | .0 |
| WACC, % | 4.97 | 4.97 | 4.97 | 4.97 | 4.97 | 4.97 | 4.97 | 4.97 | 4.97 | 4.97 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -3.7 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -4 | |||||||||
| Net Debt | -3 | |||||||||
| Equity Value | 0 | |||||||||
| Diluted Shares Outstanding, MM | 34 | |||||||||
| Equity Value Per Share | -0.01 |
What You Will Get
- Comprehensive INKT Financials: Access to both historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Real-Time Calculations: Intrinsic value and NPV are updated automatically.
- Scenario Analysis: Explore various scenarios to assess MiNK Therapeutics' future performance.
- User-Friendly Design: Crafted for professionals while remaining easy to navigate for newcomers.
Key Features
- Comprehensive DCF Calculator: Offers detailed unlevered and levered DCF valuation models tailored for MiNK Therapeutics, Inc. (INKT).
- WACC Calculator: Features a pre-built Weighted Average Cost of Capital sheet with customizable parameters specific to the biotech sector.
- Adjustable Forecast Assumptions: Easily modify growth projections, capital expenditures, and discount rates relevant to MiNK Therapeutics, Inc. (INKT).
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios specifically for MiNK Therapeutics, Inc. (INKT).
- Interactive Dashboard and Charts: Visual representations summarize essential valuation metrics for straightforward analysis.
How It Works
- Step 1: Download the prebuilt Excel template containing MiNK Therapeutics' data.
- Step 2: Review the pre-filled sheets to familiarize yourself with the essential metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly see the recalculated results, including MiNK Therapeutics' intrinsic value.
- Step 5: Make well-informed investment decisions or create reports based on the outputs.
Why Choose This Calculator for MiNK Therapeutics, Inc. (INKT)?
- User-Friendly Interface: Tailored for both novice and seasoned users.
- Customizable Inputs: Adjust parameters easily to suit your financial analysis.
- Real-Time Updates: Monitor immediate changes to MiNK Therapeutics' valuation as you modify inputs.
- Preloaded Data: Comes with MiNK Therapeutics' latest financial information for swift evaluations.
- Endorsed by Experts: Utilized by investors and analysts for strategic decision-making.
Who Should Use This Product?
- Investors: Accurately assess MiNK Therapeutics' fair value before making investment decisions.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to MiNK Therapeutics, Inc. (INKT).
- Consultants: Efficiently customize the template for valuation reports tailored to clients focused on MiNK Therapeutics.
- Entrepreneurs: Acquire insights into financial modeling practices employed by leading biotech firms.
- Educators: Implement it as a teaching resource to illustrate valuation methodologies in the biotech sector.
What the Template Contains
- Pre-Filled Data: Includes MiNK Therapeutics’ historical financials and projections.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
- Key Financial Ratios: Analyze MiNK Therapeutics’ profitability, efficiency, and leverage.
- Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
- Clear Dashboard: Charts and tables summarizing key valuation results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.